期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

华法林给药剂量预测模型的建立与应用 被引量：9

下载PDF
导出
摘要 华法林是临床上广泛应用的抗凝剂，可用于治疗房颤、深静脉血栓、肺栓塞、瓣膜移植等，而且价格便宜。但是华法林个体药物代谢能力的差异很大，治疗安全范围狭窄，影响其药效的因素又很多，
作者 庄文芳 吴婧 李莉
机构地区 上海市长宁区中心医院血液病实验室 上海交通大学附属第一人民医院检验科
出处 《检验医学》 CAS 2013年第12期1157-1161,共5页 Laboratory Medicine
关键词 剂量预测模型 华法林 单核苷酸多态性CYP2C9 VKORC1 CYP4F2
分类号 R446.11 [医药卫生—诊断学]
  • 相关文献

参考文献23

  • 1Hirsh J, Fuster V, Ansell J,et al. American HeartAssociation/ American College of CardiologyFoundation guide to warfarin therapy [ J ]. J Am CollCardiol, 2003,41(9) : 1633-1652.
  • 2张海燕,方焕荣,杨协清,罗万慰,许联红,马守梅.血浆蛋白C基因多态性与华法林剂量相关性的研究[J].中国药学杂志,2012,47(21):1741-1745. 被引量：4
  • 3Wadelius M, Chen LY, Lindh JD, et al. The largestprospective warfarin-treated cohort supports geneticforecasting!] J]. Blood, 2009 , 113(4):784-792.
  • 4Fumy a H,Fernandez-Salguero P, Gregory W, et al.Genetic polymorphism of CYP2C9 and its effect onwarfarin maintenance dose requirement in patientsundergoing anticoagulation therapy [ J ].Pharmacogenetics, 1995 , 5(6) :389-392.
  • 5Avery PJ, Jorgensen A, Hamberg AK, et al. A proposalfor an individualized pharmacogenetics-based warfarininitiation dose regimen for patients commencinganticoagulation therapy [ J ]. Clin Pharmacol Ther,2011, 90(5) :701-706.
  • 6Rost S,Fregin A, Ivaskevicius V,et al. Mutations inVKORC1 cause warfarin resistance and multiplecoagulation factor deficiency type 2 [ J ]. Nature,2004,427(6974) :537-541.
  • 7D;Andrea G, D'Ambrosio RL, Di Pema P, et al. Apolymorphism in the VKORCl gene is associated withan interindividual variability in the dose-anticoagulanteffect of warfarin [ J ]. Blood,2005 , 105 ( 2 ) : 645-649.
  • 8Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a largeinfluence on warfarin maintenance dose[ J]. Blood,2008,112(4) :1022-1027.
  • 9International Warfarin Pharmacogenetics Consortium,Klein TE, Altman RB, et al. Estimation of thewarfarin dose with clinical and pharmacogenetic data[J]. N Engl J Med, 2009,360(8) :753-764.
  • 10Limdi NA, Wadelius M, Cavallari L, et al. Warfarinpharmacogenetics : a single VKORCl polymorphism ispredictive of dose across 3 racial groups [ J ]. Blood,2010,115(18) :3827-3834.

二级参考文献23

  • 1Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent ad- verse effect resulting in regulatory action[J]. Arch Intern Med, 2007, 167(13): 1414-1419.
  • 2Klein TE, Altman RB, Eriksson N,et al. Estima- tion of the warfarin dose with clinical and pharma- cogenetic data[J]. N EnglJ Med, 2009, 360(8): 753-764.
  • 3Gage BF, Eby C, Johnson JA,et al. Use of phar- maeogenetic and clinical faetors to predict the ther- apeutic dose of warfarin[J]. Clin Pharmacol Ther, 2008, 84(3): 326-331.
  • 4Wen MS, Lee M, Chen JJ,et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes [J]. Clin Pharmacol T- her, 2008, 84(1): 83-89. pharmacogenetic algorithms.
  • 5Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindi- vidual warfarin maintenance dose: a prospective study in Chinese patients[J]. Pharmacogenet Ge- nomics, 2009, 19(3): 226-234.
  • 6Wadelius M, Chen LY, Lindh JD,et al. The largest prospective warfarin treated cohort supports genet- ic forecasting[J]. Blood, 2009, 113(4): 784- 792.
  • 7Marin-Leblanc M, Perreault S, Bahroun I, et al. Validation of warfarin in clinical praetice[J]. Pharmacogenomics, 2012, 13(1): 21-29.
  • 8Liu Y, Yang J, Xu Q,et al. Comparative perform ance of warfarin pharmacogenetic algoritlams in Chinese patients[J]. Thromb Res, 2012.
  • 9Cho H J, On YK, Bang OY, et al. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation[J]. Clin Ther, 2011, 33(10): 1371-1380.
  • 10Zhimin W, Yubao Z, Lei S, et al. Prevalence of chronic rheumatic heart disease in Chinese adults [J]. Int J Cardiol, 2006, 107(3): 356 -359.

共引文献36

同被引文献103

引证文献9

二级引证文献52

检验医学
2013年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部